Stock MGNX MACROGENICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News MacroGenics, Inc.

Equities

MGNX

US5560991094

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
16.94 USD -3.42% Intraday chart for MacroGenics, Inc. -7.68% +76.09%
Apr. 10 North American Morning Briefing : Traders Await -2- DJ
Apr. 09 TD Cowen Upgrades MacroGenics to Buy From Hold MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Traders Await -2-
DJ
TD Cowen Upgrades MacroGenics to Buy From Hold
MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading
MT
MacroGenics Shares Surge Following Phase 2 Update on Prostate Cancer Drug
MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday
MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Renewed Rate Cut Hopes
MT
Sector Update: Health Care
MT
MacroGenics Says Cancer Drug Study Update Set for May After Conference Miss
MT
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
GL
MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
CI
Transcript : MacroGenics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
JMP Securities Adjusts Price Target on MacroGenics to $22 From $16, Maintains Market Outperform Rating
MT
HC Wainwright Adjusts Price Target on MacroGenics to $16 From $14, Maintains Neutral Rating
MT
Stifel Adjusts Price Target on MacroGenics to $29 From $17, Keeps Buy Rating
MT
BMO Capital Adjusts Price Target on MacroGenics to $24 From $18, Maintains Outperform Rating
MT
MacroGenics Narrows 2023 Net Loss, Revenue Drops; Shares Fall After-Hours
MT
Transcript : MacroGenics, Inc., Q4 2023 Earnings Call, Mar 07, 2024
MacroGenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
AQ
Macrogenics Insider Sold Shares Worth $813,501, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MGNX Stock
  4. News MacroGenics, Inc.